Plain-English translation of NCT07117045 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Pancreatic Cancer research guide →This trial is testing a new screening approach for pancreatic cancer called PANDA (pancreatic cancer detection with artificial intelligence). The system combines low-dose CT imaging—a safer, lower-radiation version of standard CT scans—with advanced artificial intelligence to detect pancreatic cancer earlier, when treatment is most effective. Researchers have shown in preliminary studies that this AI system can spot pancreatic cancers that radiologists sometimes miss.
Pancreatic cancer is one of the deadliest cancers, with most patients diagnosed at advanced stages when survival rates are very low. However, patients diagnosed early have dramatically better outcomes. Current screening methods are limited and not practical for the general public. This trial aims to test whether combining low-dose imaging with AI can make early pancreatic cancer detection possible for many more people—and at lower cost and less radiation exposure than standard screening.
You likely qualify if…
You likely don't qualify if…
If you enroll, you would receive an annual low-dose CT screening scan performed with the AI system. The scan is quick, non-invasive, and uses much lower radiation than a standard abdominal CT scan. You would come in once per year for the screening, and the research team would follow up with you to track your results and overall health. The entire study involves 400,000 participants across China.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
China